Anne J. Gonzales-Luna, research assistant professor in the Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, is reporting the weakening of ...

The antibiotic vancomycin, recommended as first-line treatment for infection caused by the deadly superbug C. difficile (C. diff), may not be living up to its promise, according to new research. The ...

Kevin Garey, University of Houston Robert L. Boblitt Endowed Professor of Drug Discovery at the UH College of Pharmacy, assessed the pharmacokinetics and gut microbiome effects of oral Omadacycline in ...

Preventative oral vancomycin reduces the incidence of C. difficle during allogeneic hematopoietic stem cell transplantation, according to a study by Pittsburgh-based University of Pennsylvania ...

Scientists have discovered how the hospital superbug C.diff rapidly evolves resistance to the frontline drug used for treatment in the UK. Scientists have discovered how the hospital superbug C.diff ...

Using a diverse human gut community, researchers investigated how gut microbiota interspecies interactions affected the response of Clostridioides difficile to vancomycin and metronidazole. Findings ...

Clostridioides difficile/Clostridium difficile (C. diff) is a bacterial infection and is the most common cause of healthcare-associated diarrhea. C. diff has two distinct presentations, primary and ...

Fidaxomicin should be the antibiotic of choice when treating adults with Clostridioides difficile infection, according to new guidance from the Infectious Diseases Society of America and the Society ...

A study has linked initial vancomycin monotherapy to higher rates of Clostridium difficile infection in patients with inflammatory bowel disease, according to a report by Internal Medicine News. The ...

Clostridium difficile bacteria, computer illustration. C. difficile is a normal inhabitant of the human intestine, but it can become a pathogen when antibiotics disrupt the normal intestinal flora and ...